High-yield pathogens paired with first-line therapy, mapped to the IDSA 2024 resistant-Gram-negative guidance, the 2021 IDSA/SHEA C. difficile update, and current CDC STI recommendations.
These cards are for clinical education and board preparation. They do not replace clinical judgment, local antibiograms, institutional protocols, current prescribing references, pharmacist or infectious-diseases consultation, or patient-specific decision-making.
Antimicrobial choice depends on local susceptibility data and confirmed in-vitro susceptibilities, site of infection, severity, source control, allergy history, renal/hepatic function, pregnancy/lactation, drug interactions, and stewardship considerations. Doses and durations are deliberately summarized; verify against current references before prescribing.
Regimens are starting points for immunocompetent adults with normal organ function — always adjust for renal/hepatic function, allergy, pregnancy, and local antibiogram, and reverify against current IDSA, CDC, and product labeling before prescribing.